EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
8.0301
8.0750
Range Annuel
7.7400
11.4600
Changement quotidien
+0.37%
Changement Mensuel
+0.25%
Evolution sur 6 mois
-24.81%
Changement Annuel
-24.81%
Clôture Précédente
8.0300
Ouvrir
8.0575
Plus Bas
8.0301
High
8.0750
Volume
159
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Fabricants de Médicaments — Spécialités et Génériques
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
13.29
ratio cours/chiffre d'affaires
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

Nouvelles